Table 1: Characteristics of the eight study reports included in this meta-analysis.

Reference
number
Author (Year)Type of studyTime periodNumber of womenCohorts (n)Type of diabetesComparison(s)

[35]Di Cianni et al. (2008)Retrospectiveto December 31, 2006101Glargine (43)
NPH (58)
Type 1 DMContinuous glargine use throughout pregnancy versus cessation of glargine during pregnancy (replaced w/NPH)
[36]Egerman et al. (2009)RetrospectiveJanuary 2004 to August 2006114Glargine (65)
NPH (49)
Pregestational
Gestational
Insulin glargine versus NPH
[37]Fang et al. (2009)RetrospectiveJanuary 2003 to April 2008112Pregestational:
glargine (37),
NPH (16)
Gestational:
glargine (15)
NPH (44)
Pregestational
Gestational
Insulin glargine versus NPH Pregestational versus gestational DM
[38]Imbergamo et al. (2008)Case controlJanuary 2004 to December 200773Glargine (15)
NPH (15)
Control (43)*
Type 1 DMInsulin glargine versus NPH
Insulin glargine versus control
NPH versus control
[39]Negrato et al. (2010)Observational prospectiveJanuary 2004 to April 2009138Pregestational:
glargine (18), NPH (38)
Gestational:
glargine (37), NPH (45)
Pregestational
Gestational
Insulin glargine versus NPH Pregestational versus gestational DM
[40]Poyhonen-Alho et al. (2007)Case controlJanuary 2003 to December 200591Glargine (42)
NPH (50)
Type 1 DMInsulin glargine versus NPH
[41]Price et al. (2007)Case controlJanuary 2002 to December 200564Pregestational:
glargine (10), NPH (10) Gestational:
glargine (22), NPH (22)
Pregestational (type 1 DM)
Gestational
Insulin glargine versus NPH Pregestational versus gestational DM
[42]Smith et al. (2009)RetrospectiveJanuary 2000 to December 200552Glargine (27)
NPH (25)
Pregestational (type 1+2 DM)
Gestational
Insulin glargine versus NPH

*Control subjects were not included in the meta-analysis as they did not receive basal insulin treatment.